StockNews.AI
PTGX
StockNews.AI
105 days

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

1. Positive Phase 3 results for rusfertide in polycythemia vera announced. 2. Cash reserves of $697.9 million ensure funding through at least 2028.

Earnings
+2.57%Current Return
VS
+0.42%S&P 500
$42.0105/06 04:11 PM EDTEvent Start
$43.0905/07 10:49 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Promising trial results for rusfertide can boost investor confidence, similar to prior successful trials in biotech leading to stock price surges.

How important is it?

The article outlines key advancements and substantial financial backing, critical for future growth and potential market impact.

Why Long Term?

Positive trial outcomes lead to stronger market positioning, influencing PTGX's performance over the next fiscal periods.

Related Companies

VRTXSNAP
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025 Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CALIFORNIA / ACCESS Newswire / May 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "Protagonist is off to a very strong 2025 with multiple transformational events in the first quarter for our two late-stage partnered assets, rusfertide and icotrokinra which are progressing to NDA filings by year end," said Dinesh V.

Related News